BusinessJounce Therapeutics Appoints Perry Karsen to Its Board of DirectorsBy Nasdaq OMXJan 21, 2016, 12:00 PM UTC
BusinessPeregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy ConferencesBy Nasdaq OMXJan 20, 2016, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other CancersBy Nasdaq OMXJan 11, 2016, 1:05 PM UTC
BusinessImmune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305By Nasdaq OMXJan 8, 2016, 8:42 PM UTC
BusinessPeregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With BavituximabBy Nasdaq OMXJan 6, 2016, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXDec 7, 2015, 9:05 PM UTC
BusinessPeregrine to Report Financial Results for Second Quarter of Fiscal Year 2016 After Market Close on December 10, 2015By Nasdaq OMXDec 3, 2015, 9:05 PM UTC
